January 10, 2007 – Genentech reported above-estimate Q4 financials after the bell; ImClone said a Phase III trial showed Erbitux effective in untreated colorectal cancer patients; Genomic Health said United HealthCare will cover the costs for its breast cancer test; Cell Therapeutics filed for a SPA for the design of its Xyotax Phase III trial; King Pharmaceuticals will market the hemostatic products from Vascular Solution; Introgen said INGN 241 caused programmed cell death in lung cancer cells in a laboratory test; and MedImmune won an important, though technical, legal battle in its patent dispute with Genentech over the Cabilly patent. The Centient Biotech 200™ dropped 3 points to end at 3987, a loss of .08%. More details...
